Patients with chronic mild or moderate traumatic brain injury have abnormal longitudinal brain volume enlargement more than atrophy

David E Ross¹, John D Seabaugh¹, Jan M Seabaugh¹, Jennifer Plumley, Junghoon Ha¹, Jason A Burton², Andrew Vandervaart², Ryan Mischel², Alyson Blount³, Daniel Seabaugh¹, Katherine Shepherd¹,⁴, Justis Barcelona¹ and Alfred L Ochs¹,²; for the Alzheimer’s Disease Neuroimaging Initiative

Abstract
Introduction: Many studies have found brain atrophy in patients with traumatic brain injury (TBI), but most of those studies examined patients with moderate or severe TBI. A few recent studies in patients with chronic mild or moderate TBI found abnormally large brain volume. Some of these studies used NeuroQuant⁶, FDA-cleared software for measuring MRI brain volume. It is not known if the abnormal enlargement occurs before or after injury. The purpose of the current study was to test the hypothesis that it occurs after injury.

Methods: 55 patients with chronic mild or moderate TBI were compared to NeuroQuant⁶ normal controls (n > 4000) with respect to MRI brain volume change from before injury (time 0 [t0], estimated volume) to after injury (t1, measured volume). A subset of 36 patients were compared to the normal controls with respect to longitudinal change of brain volume after injury from t1 to t2.

Results: The patients had abnormally fast increase of brain volume for multiple brain regions, including whole brain, cerebral cortical gray matter, and subcortical regions.

Discussion: This is the first report of extensive abnormal longitudinal brain volume enlargement in patients with TBI. In particular, the findings suggested that the previously reported findings of cross-sectional brain volume abnormal enlargement were due to longitudinal enlargement after, not before, injury. Abnormal longitudinal enlargement of the posterior cingulate cortex correlated with neuropathic headaches, partially replicating a previously reported finding that was associated with neuroinflammation.

Keywords
Traumatic brain injury, magnetic resonance imaging, volumetry, NeuroQuant⁶, NeuroGage⁶

Date received: 25 September 2020; accepted: 27 April 2021

Abbreviations
CWM-cerebral white matter. GM-cerebral cortical gray matter. ICC: intraclass correlations coefficient. IFT-infratentorial. MRI-magnetic resonance imaging. mTBI-mild TBI. NQ-NeuroQuant⁶. NeuroQuanted MRI-MRI that was used for subsequent NeuroQuant⁶ brain volume analysis. SCN-subcortical nuclei. t0-time of injury. t1-time of first NeuroQuanted

¹Virginia Institute of Neuropsychiatry, Midlothian, USA
²Virginia Commonwealth University, School of Medicine, Richmond, USA
³Randolph Macon College, Undergraduate Program, Ashland, USA
⁴James Madison University, Undergraduate Program, Harrisonburg, USA

Corresponding author:
David E Ross, Virginia Institute of Neuropsychiatry, 364 Browns Hill Court, Midlothian, VA 23114, USA.
Email: DRoss@VaNeuropsychiatry.org

© The Author(s) 2021
Article reuse guidelines: sagepub.com/journals-permissions
DOI: 10.1177/20597002211018049
journals.sagepub.com/home/ccn

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Decades of research have shown that traumatic brain injury (TBI) causes brain atrophy. However, most of this research was based on patients with moderate or severe TBI. Until recently, many investigators thought that brain volume was normal in patients with mild TBI, due in part to the normal appearance of MRI scans in those patients. However, when MRI brain volume is measured, patients with chronic effects of mild or moderate TBI have been found to have volume abnormalities often but not always.

Although most studies found atrophy, a few studies found abnormal enlargement. To our knowledge, the first study to find abnormal enlargement was based on the volume estimation method, which involved estimating brain volume just before injury, measuring brain volume after injury, and comparing estimated brain volume change between patients and normal control participants. Since then, other studies have found cross-sectional abnormal enlargement or increased cortical thickness. There has been only one previous study that found longitudinal enlargement.

It is not known if the abnormal enlargement occurs before or after injury. The purpose of the current study was to test the hypothesis that it occurs after injury. More generally, because longitudinal analyses are fundamentally different from cross-sectional analyses and may be more sensitive to detecting abnormalities, the current study focused on longitudinal analyses. The methods were significantly improved from previous studies, including the following: (1) there was a greater number of patients (55 in the current study versus < 25 in most previous studies; see the Discussion section); (2) there was a greater number of brain regions analyzed (18 brain regions, including whole brain parenchyma, total cerebral cortical gray matter, cerebral white matter, multiple cortical gyral regions, and multiple subcortical regions); and (3) there was extensive use of NeuroQuant®, FDA-cleared software for measuring MRI brain volume. Unlike brain volumetric software typically used in university research settings, e.g. FreeSurfer or FSL, NeuroQuant® is readily available in clinical settings and includes age- and sex-matched data over the lifespan on over 4000 normal control participants (see the Methods section). Thus, research based on NeuroQuant® is more readily applicable in clinical situations than research confined to academic university settings. The current study provides an example of how to leverage that technology in order to better understand the effects of brain injury on TBI patients.

Methods

Participants

Patients. Selection criteria. The sample of patients was expanded from that studied and described in detail previously. In brief, patients included in this study were adult outpatients consecutively admitted to the Virginia Institute of Neuropsychiatry. They were diagnosed with traumatic brain injury according to the criteria of Menon et al. and had a mild or moderate level of brain injury according to the criteria of Silver et al. Each patient had at least one “NeuroQuanted MRI” brain scan, i.e. an MRI that was used for subsequent NeuroQuant® brain volume analysis. They had no pre-injury history of brain disorder that could affect brain volume measurements. The majority of the patients included in the study had mood disorders (e.g. depression, generalized anxiety or irritability) and posttraumatic stress disorder due to the accident or injury. This study was approved by the Sterling Institutional Review Board (approval number 6450) and satisfied the requirements of the Code of Ethics of the World Medical Association (Declaration of Helsinki) for human research. Each patient agreed to be in the study and signed the informed consent form.

Description of patient sample. 55 patients met the selection criteria. Demographic characteristics were as follows: 29 men and 26 women; mean number of years of education was 14.3 (SD 3.0; range 10–21); mean age in years at the time of the injury (t0) was 45.7 (SD 12.3; range 16.9–80.2); mean interval between time of injury and time of first MRI (t0-t1) was 1.47 years (SD 1.11; range 0.11–5.68); mean interval between t1 and t2 MRIs (t1-t2) was 0.62 years (SD 0.27; range 0.22–1.59).

Because all 55 patients had at least 1 MRI brain scan, t0-t1 brain volume analyses (see below for details) were performed for all of them. A subset of patients had 2 MRI brain scans available (N = 36) allowing for t1-t2 longitudinal analyses.

Causes of injury included motor vehicle accident (n = 44), train accident (n = 4), hit to head with object (n = 4), fall down steps (n = 1), mining accident (n = 1), and motor vehicle vs. pedestrian accident (n = 1).

48 patients had mild TBI and 7 patients had moderate TBI. The mean GCS score was 14.7, median 15.0, range 11–15. The mean duration of loss of consciousness was 2.4 minutes, median 0, range 0–30 minutes. The median duration of posttraumatic amnesia was 0.33 hours, range 0–408 hours.

Regarding other neuropsychiatric symptoms due to the brain injury, in general, the sample of patients had...
a wide range of chronic symptoms including impaired cognition, impaired mood, impaired sleep and wakefulness, posttraumatic stress disorder, and pain, which caused them to seek treatment at a TBI specialty outpatient clinic. The mean score on the Glasgow Outcome Scale-Extended version (GOS-E) was 5.5 (SD = 0.6). The vast majority of patients had either GOS-E = 5 (consistent with Lower Moderate Disability [LMD]) or 6 (consistent with Upper Moderate Disability [UMD]). The main difference between patients with LMD and UMD was that most patients with LMD were unable to work and most patients with UMD were able to work despite some impairment in work ability. 52.9% of the patients were able to return to work (although almost always with difficulty), and 47.1% of the patients were unable to return to work.

**Two sets of normal control data.** Two sets of normal control data were used for this study: one based on NeuroQuant® software (https://www.cortechslabs.com/products/neuroquant) and the other based on NeuroGage® software (http://www.neurogage.com). These software programs are described in the Brain imaging and volume measurement section, “Brain imaging and volume measurement.” The normal control data associated with them are described in next two subsequent sections, just below. These two sets of data were used for their complementary strengths, described below in the Brain imaging and volume measurement section.

**NeuroQuant® normal control data.** NeuroQuant® normal control data came from the NeuroQuant® software produced by CorTechs Labs, Inc. (https://www.cortechslabs.com) (San Diego, CA, USA). NeuroQuant® is FDA-cleared software for measuring MRI brain volume and assessing for abnormal brain volume (for further details, see the Brain imaging and volume measurement section, “Brain imaging and volume measurement”).

An advantage of the NeuroQuant® normal control data over most other normal control data sets was that it included a very large number (over 4000) of normal control participants (that number was based on personal communication with Weidong Luo, Senior Scientist, CorTechs Labs Inc., March 23, 2020) collected from a variety of sources. The ages of the NeuroQuant® normal controls ranged from 3 to 100 years. The NeuroQuant® software was designed to compare the MRI brain volume data for each subject to that of a large database of normal controls, matched for age and sex. The large number of normal controls and range of ages allowed for more accurate estimates of normal brain volume throughout the lifespan than most other normal control datasets. In the current study, these features of NeuroQuant® allowed for accurate between-group analyses of brain volume while minimizing the effects of age and sex.

In order to take advantage of these features of NeuroQuant®, each patient and each NeuroGage® normal control (for explanation of “NeuroGage® normal control” see the next section) was analyzed using the NeuroQuant® Triage Brain Atrophy analysis (https://www.cortechslabs.com/products/neuroquant/tba), which created a normative percentile for each brain region after matching the patient’s age and sex to the normal control database, and adjusting for intracranial volume. The Triage Brain Atrophy report includes dozens of brain regions, including cortical gray matter, cerebral white matter, multiple cortical gyral regions, basal ganglia and other subcortical regions, brainstem and cerebellum.

For the current study, the normative percentiles were converted to Z scores in order to allow the use of parametric statistics. Because the normative percentiles—and in turn, the Z scores—were based on a procedure that minimized the effects of age, sex and intracranial volume on brain volume (as described in the NeuroQuant® cross-sectional analyses section below), it was not necessary to compare patient and normal control volume data—or further adjust the volume data—with respect to those variables.

NeuroQuant® does not provide information about level of education for its normal controls. Regarding potential effects of education on brain volume, the mean years of education of the patients (n = 55) was 14.3 (SD = 3.0), which was similar to the mean years of education for the U.S.A. population in 2012 (13.3 years; http://data.uis.unesco.org/index.aspx?queryid = 242), which was considered to be the best estimate of the mean years of education of the NeuroQuant® normal control group.

**NeuroGage® normal control data.** Despite the multiple advantages of NeuroQuant’s normal control data, it did not provide data on variability (SD) of longitudinal volume change. Therefore, a second set of normal control data, based on NeuroGage® software, was used to measure normal variability of volume change. The NeuroGage® normal control participants are described in this section, and the use of NeuroGage® normal control data to measure variability is described in the Brain imaging and volume measurement section, “Brain imaging and volume measurement.”

The NeuroGage® 2.0 normal control participants were described previously. The group included 80 normal control participants whose MRI brain scans were obtained from a larger group previously studied as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The ADNI normal control subjects were selected to be healthy and free of cognitive...
and other medical problems that would affect brain volume measurement. The ADNI MRI data have been used in numerous peer-reviewed publications; a search of the term “ADNI” in PubMed returned 1534 publications. For more details about ADNI, see the cited references.26–28

The NeuroGage® normal control group consisted of 80 participants (N = 40 women and 40 men; mean age (in years) = 68.4, SD 3.2, median 70, range 60–72). The NeuroGage® normal controls were significantly older (mean = 68.4 years, SD = 3.2) than the patients (mean = 47.2, SD = 12.3)(t = -12.56, df = 59.2, p < .0001). Because the NeuroGage® normal control data were used only to measure variance of change of brain volume, and since that was likely to increase with age, the older age of the normals controls likely led to less ability to find statistically significant differences between the patient and normal control groups, a conservative limitation. The mean interval between t1 and t2 MRIs (t1-t2) was 1.06 years (SD 0.07; range 0.82–1.29).

**Brain imaging and volume measurement**

**Magnetic resonance imaging.** Each participant had one or more MRI brain scans at one of various radiology centers using the scanning protocol recommended for allowing later NeuroQuant® analysis; this protocol is described in detail on the NeuroQuant® website (http://www.cortechs.net/products/neuroquant.php). In addition to the general requirements for having an MRI (e.g., having no magnetic metal in the body), the NeuroQuant® protocol required, at a minimum, the following:

- MRI scanner which supported the NeuroQuant® scanning protocol
- MRI scanning protocol based on the ADNI scanning protocol
- T1-weighted timing sequence
- Non-contrast
- Sagittal
- 3D

All patients had 3.0 Tesla scans, instead of 1.5 Tesla scans, in order to have higher scan resolution for clinical purposes. Normal control participants from the NeuroQuant® and NeuroGage® normal control groups were scanned with either 1.5T or 3.0T scanners.

NeuroQuant® is FDA-cleared to be used on a variety of scanners, using 1.5T or 3.0T magnets, indicating good reliability between scanners and magnet strengths for the volume measurements (https://www.cortechslabs.com/resources/technical-information/recommended-scanner-settings).

For longitudinal analyses, patients and NeuroGage® normal controls had a second MRI brain scan performed on the same scanner as their first scan in order to eliminate within-subject interscanner differences.

**NeuroQuant® software was used for cross-sectional brain volume analysis.** All cross-sectional MRI brain volumes were measured using NeuroQuant®, FDA-cleared software for measuring MRI brain volume in humans. In addition to its FDA clearance, the reliability and validity of NeuroQuant® has been supported by over 91 peer-reviewed publications (supplemental online file “All NQ pubs_COPY” https://www.dropbox.com/sh/n96hsfrgu4lg0iv/AAC-rgKkrMdibBxBxSIT7KE4cGa?dl=0). These include multiple studies that found that NeuroQuant® is reliable for measuring brain volume in normal subjects, patients with TBI, and other neuropsychiatric patients and valid for assessing brain volume in patients with TBI.4,5,8,12,16,19,25,33,35–41

Neuroquant® automated brain MRI segmentation. The brain MRI grayscale images for each patient and NeuroGage® normal control® were uploaded to the NeuroQuant® server, which processed and analyzed the brain imaging data. The output of the NeuroQuant® computer-automated analysis included one or more reports that contained volumetric information, and a set of segmented (colored) brain images that were visually inspected for errors by one of the authors (D.E.R), in order to ensure accurate identification of brain regions by the software, using our previously described quality control procedure.42 For the normal controls, there were no segmentation errors. For the patients, 1.5% of brain regions were judged to have been identified inaccurately by NeuroQuant®, and therefore those data were omitted from subsequent analyses. Therefore, 98.5% of brain volume data were included for the patients, including the large majority of brain volume data for each patient.

NeuroQuant® cross-sectional analyses. All patients were analyzed using the NeuroQuant® 2.3 Triage Brain Atrophy report (https://www.cortechslabs.com/products/neuroquant/tba), which included 44 brain regions, including cortical gray matter, cerebral white matter, basal ganglia, infratentorial regions, and numerous cortical gray matter regions. These reports provided normative percentiles for each cross-sectional brain volume after adjusting the volumes for intracranial volume (by dividing by intracranial volume), matching for age (by comparing the subject’s volume to normal controls of the same age) and matching for sex (by comparing the volume to normal controls of the same age).
published brain volume estimation method, and volume was estimated at \( t_0 \) using our previously published NeuroQuant MRI. In the current study, reliability of the volume estimation method was tested in a similar fashion but instead using the current 80 NeuroGage normal control group (\( N = 20 \)) by comparing measured brain volumes to estimated brain volumes using intraclass correlation coefficients (ICCs).

In the current study, reliability of the volume estimation method was tested in a similar fashion but instead using the current 80 NeuroGage normal controls (for details of statistical methods for testing reliability, see the next section). Reliability again was found to be good for the 4 brain regions (\( \text{WBP}, \text{GM}, \text{CWM}, \text{SCN+IFT} \)) for details, see the Reliability section).

For brain volume change from \( t_0 \)-\( t_1 \), for both patients and normal controls, brain volume was estimated at \( t_0 \) and measured at \( t_1 \) (for normal controls, because they were not injured, there actually was no \( t_0 \) data; so their \( t_1 \) data served as a proxy for \( t_0 \) date of injury data, and their \( t_2 \) data served as a proxy for \( t_1 \) date regarding date of injury and volume measurement). For details about this procedure see.\(^{16}\)

Accordingly, brain volume change was estimated from time 0 (\( t_0 \)) to time 1 (\( t_1 \)). Annualized percentage change of brain volume was calculated using the standard approach as follows: 1) calculate Volume Change as the change from \( t_0 \) to \( t_1 \) = [(Volume at \( t_0 \)) - (Volume at \( t_1 \))]; 2) calculate Proportion Change = (Volume Change/VOLUME at \( t_0 \))\(^{\text{\%}}\); 3) calculate Percentage Change = (Proportion Change \times 100\%)\(^{\text{\%}}\); and 4) calculate Percentage Change per year = [Percentage Change/\( (t_0 \text{-}t_1 \) interval measured in years)].

For each patient, in order to adjust for the effects of age and sex on annualized percentage change of brain volume, each patient’s volume change was compared to the corresponding age- and sex-matched NeuroQuant normal control group data. This method involved converting each patient’s data to a Z score as follows: 1) Subtract the patient’s value from the mean of the age-
matched and sex-matched NeuroQuant® normal control group data; and 2) divide the result by the standard deviation (SD) of t0-t1 volume change values based on the NeuroGage® normal control data. Regarding the latter step, the SD of t0-t1 values based on the NeuroGage® normal control data were used as an estimate of the SD of t0-t1 values based on the NeuroQuant® normal control data, since the latter were not available; this was similar to our previously published approach.12

t1-t2 analyses. For the t1-t2 longitudinal analyses, brain volume change and Z score calculations were performed using the same methods that were used for the t0-t1 analyses, except that volume was measured—not estimated—at both time points (t1 and t2). 18 brain regions had NeuroQuant® normal control data available throughout the adult life span allowing t1-t2 analyses for those regions. An example of the longitudinal analysis method applied to a single patient for t1-t2 calculations is depicted in Figure 2.

Statistical analyses

Inspection of distributions of data. Distributions of data were inspected for outliers and distributional characteristics. All the t0-t1, t1-t2, t1 and t2 data were at least approximately normally distributed based on visual inspection of the histograms; therefore, parametric statistics were used.

Testing reliability. Test-retest reliability for NeuroQuant® software versions 2.0 and 2.3 was assessed in the NeuroGage® normal controls using our previously described methods.8,33

The reliability of the volume estimation method was assessed by comparing estimated to measured brain volumes in the normal controls, as described above in the t0-t1 longitudinal analyses section. Reliabilities were calculated for each brain region using intraclass correlations coefficients (ICCs; 3, 1) based on the terminology of Shrout and Fleiss44 using SPSS version 25 (Model = 2-Way Mixed; Type = Absolute agreement; Confidence Interval = 95%). To interpret ICC values, the following guidelines were used: ICC < 0.5 indicated poor reliability, 0.5 < ICC < 0.75 indicated moderate reliability, 0.75 < ICC < 0.9 indicated good reliability, and ICC > 0.9 indicated excellent reliability.45

Comparisons between groups. Two-tailed Z tests were used for all group comparisons, with the NeuroQuant® normal control group expected by design to have a mean of 0 and SD of 1 for each brain region volume.

Figure 1. Example of application of t0-t1 brain volume estimation method in female patient who had TBI at 43.9 years of age. Top: At t0 (time of injury, indicated by open circle), her cortical gray matter volume was estimated to be equal to the mean of normal women her age (based on the NeuroQuant® normal control data). At t1 (time of first NeuroQuanted MRI, indicated by solid circle), she was 44.1 years old, and her volume was measured and found to be increased from the pre-injury estimate. This top figure is based on the NeuroQuant® report, except for the open circle and boxed key, which was added by the authors. Bottom: NeuroGage® analysis showed that her estimated rate of brain volume increase was 9.4% per year from t0-t1 (solid circle, plotted at the midpoint of the interscan interval, age 44.0). The normal mean % change of volume per year (50th normative %tile function in this bottom figure) was determined by differentiating the mean volume (50th normative %tile function in the top figure) with respect to time and was found to be −0.26%/year at age 44.0 years. The normal standard deviation of % volume change per year was calculated to be 4.61% per year, based on the NeuroGage® normal control data. The 95th and 5th normative percentiles were calculated as the mean % volume change per year ± 1.6449 standard deviations respectively. A Z-score was calculated as the patient’s data (9.4%/year) minus the normal mean (−0.26%/year), the quantity divided by the normal SD (4.61%/year), which equalled 2.1, corresponding to the 98.3 normative %tile. Her Z score of 2.1 was used in the group analyses.
Results were reported with and without adjustments for multiple comparisons. Such adjustments reduce Type 1 errors (false positive findings) at the expense of increasing Type 2 statistical errors (false negative findings), and for this and other reasons previous authors have argued against using such adjustments. For the current study, Type 2 errors were judged to be at least as important as Type 1 errors. However, other investigators believe that some adjustment is needed to control the risk of Type 1 error. In the current study, we used the following approach: 1) results were reported with Bonferroni adjustments; and 2) also results were reported without adjustments, and calculations regarding the number of positive findings expected by chance alone were provided with each set of unadjusted analyses in order for providing a framework for interpreting the risk of Type 1 error. Accordingly, results associated with significant unadjusted P values but nonsignificant adjusted P values should be interpreted with more caution.

Statistical software. JMP Pro version 14.0.0 was used to perform all statistical analyses except the intraclass correlations, which were performed using SPSS version 25.

Results

Reliability

ICCs comparing NeuroQuant® 2.0 to 2.3 software versions ranged from 0.95 to 1.00, showing excellent reliability for all brain regions (online supplementary file “ICCs for NQ 2.0 v 2.3” https://www.dropbox.com/sh/n96hsfrgu4lg0iv/AAC-rgKKrMdbxSIT7KE4cGa?dl=0). Therefore, the volume results from either software version were considered to be interchangeable for the purposes of the current study.

ICCs comparing measured brain volumes to estimated brain volumes showed that reliabilities ranged from good to excellent: WBP (.92), GM (.85), CWM (.77), and SCN+IFT (.77) (see figures in online supplementary file “Reliability of vol estim method” https://www.dropbox.com/sh/n96hsfrgu4lg0iv/AAC-rgKKrMdbxSIT7KE4cGa?dl=0).

Comparing patients to normal controls for t0-t1 volume change

The groups of patients and normal controls were compared with respect to estimated change of brain volume from time 0 (t0) to time 1 (t1) (Table 1). The patients had more regions of abnormal t0-t1 volume change (4 of 4 regions with P < .05) than would have been expected by chance alone (5% abnormally small + 5% abnormally large = 10% abnormal; 10%x4
regions = 0.4 regions). Cerebral white matter atrophied abnormally fast, and the other 3 regions enlarged abnormally fast. 2 of the 4 regions survived Bonferroni corrections.

**Comparing patients to normal controls for t1-t2 volume change**

The groups of patients and normal controls were compared with respect to change of brain volume from t1 to t2 (Table 2). The patients had more regions of abnormal t1-t2 volume change (9 of 18 regions with P < .05) than would have been expected by chance alone (5% abnormally small + 5% abnormally large = 10% abnormal; 10% x 18 regions = 1.8 regions). All abnormal volume changes involved longitudinal parenchymal enlargement (or similarly, ventricular diminution). 6 of 9 regions survived Bonferroni correction.

Graphs of volume change (t0-t1 and t1-t2) versus time after injury are shown in Figures 3 to 5.

**Comparing patients to normal controls for t2 volume**

The groups of patients and NeuroQuant® normal controls were compared with respect to cross-sectional brain volume at t2, and the results are shown in

---

**Table 1. Comparisons of brain volume changes from time 0 (t0) to time 1 (t1) between patients and NeuroQuant® normal controls (converted to Z scores), where t0 was the time just before injury, and t1 was the time of the first NeuroQuanted MRI.**

| Brain region                              | Mean  | SD    | Z-test statistic | df  | Sig. (2-tailed) | Effect size d |
|-------------------------------------------|-------|-------|-----------------|-----|----------------|---------------|
| Whole brain parenchyma                    | 0.30  | 1.39  | 2.24            | 54  | 0.02*          | 0.25          |
| Cortical gray matter                      | 0.54  | 1.68  | 3.95            | 53  | <0.0001*       | 0.40          |
| Cerebral white matter                     | -0.38 | 1.49  | -2.83           | 53  | 0.005*         | -0.31         |
| Subcortical nuclei + infratentorial regions| 0.89  | 3.02  | 6.59            | 54  | <0.0001*       | 0.44          |

Volume was estimated at t0 and measured at t1; therefore, the t0-t1 change scores were estimates of volume change. Four regions were included because these were the only regions that had sufficient reliability for the volume estimation method, based on comparison of measured volumes versus estimated volumes. They were the four largest regions of the brain, which probably contributed to their correlations with intracranial volume and therefore to their reliability for this method. The results showed that the patients had abnormal longitudinal volume changes in all 4 regions with small-to-medium effect sizes.

*Asterisks and **bold font** indicate regions associated with P values < .05.

†Crosses indicate regions associated with Bonferroni-adjusted P values < .0023 ( = 0.05/22 tests for t0-t1 and t1-t2 group comparisons).

---

**Table 2. Comparisons of brain volume changes from time 1 (t1) to time 2 (t2) between patients and NeuroQuant® normal controls (converted to Z scores), where t1 was the time of the first NeuroQuanted MRI, and t2 was the time of the second NeuroQuanted MRI.**

| Brain region                              | Mean  | SD    | Z-test statistic | df  | Sig. (2-tailed) | Effect size d |
|-------------------------------------------|-------|-------|-----------------|-----|----------------|---------------|
| Whole brain parenchyma                    | 0.72  | 2.83  | 4.24            | 34  | 0.002*                 | 0.37          |
| Cortical gray matter                      | 0.94  | 2.70  | 5.54            | 34  | 0.001*                 | 0.51          |
| Cerebral white matter                     | -0.03 | 1.51  | -0.18           | 34  | 0.86                 | -0.02         |
| Subcortical nuclei + infratentorial regions| 0.35  | 3.09  | 2.13            | 35  | 0.03*                 | 0.17          |
| Superior lateral ventricles               | -0.738| 2.90  | -4.43           | 35  | <0.0001*               | -0.38         |
| Third ventricle                           | -0.20 | 4.18  | -1.18           | 35  | 0.24                 | -0.08         |
| Inferior lateral ventricles               | -0.36 | 2.31  | -2.17           | 35  | 0.03*                 | -0.22         |
| Cerebellar white matter                   | 0.15  | 2.94  | 0.92            | 35  | 0.36                 | 0.08          |
| Thalamus                                  | 0.23  | 2.39  | 1.38            | 35  | 0.17                 | 0.14          |
| Ventral diencephalon                      | 0.00  | 3.00  | 0.01            | 35  | 0.99                 | 0.00          |
| Nucleus accumbens                         | 0.34  | 2.53  | 2.06            | 35  | 0.36                 | 0.08          |
| Primary motor                             | 0.30  | 1.89  | 1.77            | 35  | 0.08                 | 0.20          |
| Medial parietal                           | 0.89  | 3.14  | 5.25            | 34  | <0.0001*               | 0.43          |
| Inferior parietal                         | 0.22  | 2.35  | 1.30            | 34  | 0.19                 | 0.13          |
| Medial occipital                          | -0.14 | 2.75  | -0.85           | 34  | 0.40                 | -0.08         |
| Middle temporal                           | 0.73  | 2.70  | 4.29            | 34  | <0.0001*               | 0.39          |
| Fusiform                                  | 0.53  | 2.15  | 3.15            | 34  | 0.002*                | 0.34          |
| Hippocampus                               | 0.24  | 1.94  | 1.44            | 34  | 0.15                 | 0.17          |

18 brain regions were included because resources were available to obtain NeuroQuant graphs of normal volume change throughout the lifespan for only 18 regions. The results showed that the patients had many areas of abnormal longitudinal parenchymal volume enlargement (or similarly, ventricular diminution) with small to medium effect sizes.

*Asterisks and **bold font** indicate regions associated with P values < .05.

†Crosses indicate regions associated with Bonferroni-adjusted P values < .0023 ( = 0.05/18 tests for t0-t1 and t1-t2 group comparisons).
Table 3. (Recently we reported a similar analysis for t1 data\textsuperscript{19}). The patients had more regions of abnormal t2 volume (25 of 39 regions with $P < 0.05$) than would have been expected by chance alone ($5\%$ abnormally small, $+5\%$ abnormally large $= 10\%$ abnormal; $10\% \times 39$ regions $= 3.9$ regions). 22 of the regions were abnormally large, and 3 regions were abnormally small. Sixteen of the 25 regions survived Bonferroni correction.

**Discussion**

**Main findings**

The main findings of this study were that patients with chronic mild or moderate TBI had abnormally fast longitudinal enlargement of multiple brain regions, including cerebral cortical gray matter, subcortical nuclei + infratentorial regions (SCN+IFT), and several cortical gyral regions.

**Abnormal longitudinal brain volume changes**

**Summary of longitudinal findings.** More specifically, the brain volume estimation method was used to estimate volume at t0 (just before injury) and compare it to volume measured at t1 (after injury). Based on this method, cortical gray matter and SCN+IFT enlarged abnormally fast. The latter two findings constituted a partial replication of our previous findings, which were based on a subsample of the current patients.\textsuperscript{12,16}

Longitudinal enlargement of SCN+IFT from t0-t1, 

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Cortical gray matter volume (measured at t1 and t2) and volume change (measured from t0-t1 and t1-t2) versus time after injury. The following comments about sections (a) through (c) apply to Figures 3 through 5. For sections (a) and (b), patient data are shown as individual data points and averaged over bins to examine trends over time. Section (c) is a zoom-in on the trendlines from section (b), achieved by omitting the individual data points. Because the patients were screened to exclude those who had pre-injury disorders affecting brain volume, it was likely that they had normal brain volume or volume change ($Z$ score $= 0$) before injury (at t0). Therefore, for each graph, a theoretical line was drawn from the point ($x = 0$, volume $Z$ score $= 0$) to the first data point based on the average of measured data, and the line was dashed to indicate that it was a theoretical trendline. (a) Volumes (t1 and t2) reached medium effect sizes ($Z$ scores around 0.5) within a few months after injury and plateaued for over 2 years. (b) Volume changes (t0-t1 [estimated] and t1-t2 [measured]) reached large effect sizes ($Z$ scores around 1) within a couple months after injury and decreased partially for the next two years ($Z$ scores averaging around 0.6), indicating that volume was enlarging at a rapid pace through the first year but at a more moderate pace during the second and third years after injury. (c) Zoom-in on the trendlines from section (b).

Table 3. (Recently we reported a similar analysis for t1 data\textsuperscript{19}). The patients had more regions of abnormal t2 volume (25 of 39 regions with $P < 0.05$) than would have been expected by chance alone ($5\%$ abnormally small, $+5\%$ abnormally large $= 10\%$ abnormal; $10\% \times 39$ regions $= 3.9$ regions). 22 of the regions were abnormally large, and 3 regions were abnormally small. Sixteen of the 25 regions survived Bonferroni correction.
found in the current study, correlated anatomically with the previously reported t1 cross-sectional enlargement of several of the subcomponents of SCN+IFT, including cerebellar white matter, thalamus, ventral diencephalon, caudate nucleus, amygdala and hippocampus.19

Cerebral white matter appeared to atrophy during the t0-t1 interval, with a small to medium effect size (d = -0.31). However, the associated statistical test of inference (with P = .005) did not survive Bonferroni adjustment (adjusted alpha = .0023), raising a question about whether it was due to a Type 1 statistical error. Was there evidence to suggest that it was a valid finding? Figure 4 showed that, if there was atrophy, it occurred mostly within the first year after injury. A post hoc exploratory analysis showed that cerebral white matter atrophied in the subset of patients scanned within 1 year after injury (N = 21 patients, mean Z score = -0.87, SD = 2.25, Z-test statistic = -3.97, df = 20, P < .0001, effect size d = -.53). In our previous study, which was based on a subset of the current sample of patients, we presented evidence that there was cross-sectional atrophy of cerebral white matter, especially within the first year after injury19 (p. 14). More generally, there have been previous reports of longitudinal cerebral white matter atrophy in patients with chronic mild TBI9 and chronic moderate or severe TBI (for reviews, see1,2). Overall, in patients with chronic mild or moderate TBI, it seemed likely that there was longitudinal cerebral white matter atrophy within the first year of injury (but not after the first year), and that finding should be considered preliminary.

Traditional longitudinal measurements (t1-t2 change), based on measuring—not estimating—t1 and t2 volumes, showed abnormal enlargement of whole brain parenchyma, cortical gray matter, and several
Figure 5. Subcortical nuclei + infratentorial regions (SCN+IFT) volume (measured at t1 and t2) and volume change (measured from t0-t1 and t1-t2) versus time after injury. (a) Volumes (t1 and t2) reached large effect sizes (Z scores around 0.8) within 10 months after injury and decreased partially over the next 2 years. (b) Volume changes (t0-t1 [estimated] and t1-t2 [measured]) reached very large effect sizes (Z scores around 2.2) within a couple months after injury, and then steadily decreased until 3 years after injury, indicating that volume was enlarging through the first year, changing little during the second year, but atrophying around 3 years after injury. (c) Zoom-in on the trendlines from section (b).
Table 3. Comparisons of cross-sectional brain volumes at time 2 (t2) between patients and NeuroQuant® normal controls (converted to Z scores), where t2 was the time of the second NeuroQuanted MRI.

| Brain region                  | Mean  | SD    | Z-test statistic | df  | Sig. (2-tailed) | Effect size d |
|------------------------------|-------|-------|------------------|-----|-----------------|---------------|
| Cerebral white matter        | −0.07 | 0.94  | −0.42            | 35  | .67             | −0.07         |
| Cortical gray matter         | 0.52  | 0.94  | 3.13             | 35  | **.002***       | 0.54          |
| Ventricles                   | −0.17 | 1.13  | −1.01            | 35  | .31             | −0.16         |
| Subcortical structures       |       |       |                  |     |                 |               |
| Cerebellar white matter      | 0.92  | 1.03  | 5.52             | 35  | <.0001*†        | 0.906         |
| Cerebellar gray matter       | −0.03 | 1.06  | −0.20            | 35  | .85             | −0.03         |
| Brainstem                    | 0.26  | 1.00  | 1.59             | 35  | .11             | 0.26          |
| Thalamus                     | 1.17  | 1.06  | 7.01             | 35  | <.0001*†        | 1.13          |
| Ventral diencephalon         | 0.36  | 0.86  | 2.18             | 35  | **.03***        | 0.392         |
| Basal ganglia                |       |       |                  |     |                 |               |
| Putamen                      | 0.04  | 0.85  | 0.25             | 35  | .80             | 0.05          |
| Caudate                      | 0.31  | 0.98  | 1.85             | 35  | .06             | 0.31          |
| Nucleus accumbens            | 0.28  | 1.18  | 1.68             | 35  | .09             | 0.26          |
| Pallidum                     | −0.50 | 0.85  | −3.01            | 35  | **.003***       | −0.54         |
| Cingulate                    | 0.83  | 1.23  | 4.97             | 35  | <.0001*†        | 0.74          |
| Anterior cingulate gyrus     | 0.66  | 1.43  | 3.98             | 35  | <.0001*†        | 0.55          |
| Posterior cingulate gyrus    | 0.56  | 0.96  | 3.34             | 35  | **.001*†        | 0.57          |
| Isthmus cingulate gyrus      | 0.35  | 1.19  | 2.10             | 35  | **.04***        | 0.32          |
| Frontal lobes                | 0.22  | 1.02  | 1.33             | 35  | .18             | 0.22          |
| Superior frontal gyrus       | −0.09 | 0.96  | −0.51            | 35  | .61             | −0.09         |
| Middle frontal gyrus         | 0.63  | 0.92  | 3.79             | 35  | **.0002†        | 0.66          |
| Inferior frontal gyrus       | −0.07 | 0.98  | −0.42            | 35  | .68             | −0.07         |
| Lateral orbitofrontal gyrus  | −0.18 | 1.37  | −1.08            | 35  | .28             | −0.15         |
| Medial orbitofrontal gyrus   | −0.68 | 1.08  | −4.06            | 35  | <.0001*†        | −0.65         |
| Paracentral region           | 0.43  | 0.89  | 2.60             | 35  | **.009*†        | 0.46          |
| Primary motor region         | 0.70  | 0.97  | 4.19             | 35  | <.0001*†        | 0.71          |
| Parietal lobes               | 0.97  | 0.90  | 5.81             | 35  | <.0001*†        | 1.02          |
| Primary sensory region       | 0.65  | 0.98  | 3.90             | 35  | <.0001*†        | 0.66          |
| Medial parietal              | 0.89  | 1.04  | 5.35             | 35  | <.0001*†        | 0.88          |
| Superior parietal            | 0.37  | 1.06  | 2.23             | 35  | **.03***        | 0.36          |
| Inferior parietal            | 1.25  | 0.79  | 7.50             | 35  | <.0001*†        | 1.40          |
| Supramarginal                | 0.23  | 0.97  | 1.36             | 35  | .17             | 0.23          |
| Occipital lobes              | 0.43  | 1.07  | 2.60             | 35  | **.01*†         | 0.42          |
| Medial occipital             | 0.71  | 1.06  | 4.26             | 35  | <.0001*†        | 0.69          |
| Lateral occipital            | 0.11  | 1.11  | 0.67             | 35  | .50             | 0.11          |
| Temporal lobes               | 0.19  | 0.89  | 1.16             | 35  | .25             | 0.20          |
| Transverse temporal + superior temporal | 0.18  | 1.04  | 1.06             | 35  | .29             | 0.17          |
| Posterior superior temporal sulcus | 0.38  | 1.09  | 2.29             | 35  | **.02*†         | 0.37          |
| Middle temporal              | −0.30 | 1.06  | −1.82            | 35  | .07             | −0.29         |
| Inferior temporal            | −0.40 | 0.99  | −2.40            | 35  | **.02*†         | −0.40         |
| Fusiform                     | 0.81  | 0.98  | 4.84             | 35  | <.0001*†        | 0.81          |
| Parahippocampus              | 0.12  | 0.91  | 0.70             | 35  | .48             | 0.12          |
| Entorhinal                   | 0.18  | 1.14  | 1.11             | 35  | .27             | 0.17          |
| Temporal pole                | −0.01 | 1.07  | −0.05            | 35  | .96             | −0.01         |
| Amygdala                     | 0.93  | 0.88  | 5.60             | 35  | <.0001*†        | 0.99          |
| Hippocampus                  | 1.19  | 0.94  | 7.15             | 35  | <.0001*†        | 1.23          |

39 regions were included because that was the number of brain regions included on the NeuroQuant® Triage Brain Atrophy report. The results showed that the patients had many regions of abnormal volume, mostly enlargement, but some atrophy.

* Asterisks and **bold font** indicate regions associated with $P$ values < .05.

† Crosses indicate regions associated with Bonferroni-adjusted $P$ values < 0.0013 ($= 0.05/39$ tests).
cortical gray matter subregions, including the medial parietal cortex, middle temporal gyrus and fusiform gyrus. Similarly, there was progressive diminution of the superior lateral ventricles, consistent with longitudinal enlargement of adjacent parenchymal regions.

Examination of the relationships between longitudinal volume changes and time after injury (Figures 1 to 3) showed different patterns for the 3 major subdivisions of the brain as defined in this study: 1) for cortical gray matter, volume enlarged rapidly within the first few months after injury and continued to enlarge until approximately 3 years after injury; 2) for cerebral white matter, volume decreased rapidly within the first few months after injury then tended to plateau over the next couple years; and 3) for SCN+IFT, volume enlarged rapidly within the first few months after injury but began decreasing around 2 or 3 years after injury.

**Literature review.** Although there have been many reports of longitudinal brain atrophy in patients with moderate to severe TBI (for review, see 1–3,21), the pattern of volume abnormalities in mild to moderate TBI is less clear. Table 4 shows a brief review of 9 previous longitudinal studies that were similar to the current study; that is, they involved adult patients with mild or moderate TBI, measured brain volume or cortical thickness, and involved mechanisms of injury such as motor vehicle accidents and falls, not military or sports injuries.

The finding of abnormally fast enlargement of whole brain parenchymal volume has not been reported previously and stands in contrast to reports of longitudinal atrophy by our group and others.6–8,12 However, the study by Hofman et al. had no control group (so whole brain volume decreased significantly, but it was not clear if the rate of decrease was abnormally fast); and the study by MacKenzie et al. had only 7 patients and 4 normal controls. It was not clear why our current study differed from our previous studies with respect to this finding, but possibilities include improved methods of our current study as follows: 1) much larger sample sizes; 2) a later, improved version of NeuroQuant® software (software version 2 versus software version 1); 3) use of age-matched normal control data in the current study but not in the earlier ones; 4) increased levels of treatment and rehabilitation in our patients over the years possibly led to greater brain volume enlargement.47

The finding of abnormally fast increase of total cerebral cortical gray matter volume from t0-t1 (with an effect size of 0.4) was consistent with our previous finding,12 which also found an effect size of 0.4; but the effect size in the previous study was not associated with a significant result for the associated test of statistical inference, which in retrospect probably was due to lower power than in the current study. The findings of enlargement of cortical gray matter for t0-t1 and t1-t2 in the current study generally was consistent with previous findings of longitudinal thickening of multiple cortical gray matter regions.15 However, two other studies found longitudinal atrophy (decreased volume or cortical thickness) of cortical gray matter regions.9,13 The reasons for the different findings were not clear but could have been due to multiple differences in methods.

The finding of abnormally fast cerebral white matter atrophy was a partial replication of our previous studies, which was based on a smaller subset of the current sample of patients.8,12,16 Atrophy of white matter in cingulate regions was reported by Zhou et al.9 No other studies of patients similar to ours reported cerebral white matter atrophy, but most of the other studies measured whole brain parenchymal volume or cortical gray matter volume (or thickness) and not cerebral white matter.

The finding of abnormally fast increase of SCN+IFT also was a partial replication of our previous studies.8,12 The finding generally was inconsistent with the previously reported findings of longitudinal atrophy of the caudate, putamen and amygdala,17 although SCN+IFT includes many regions other than just the ones reported by Zagorchev et al.

In summary, our literature review of longitudinal studies of MRI brain volume in patients similar to ours (including our previous studies) found that few studies existed, and the results generally were mixed. The most agreement was found for cerebral white matter atrophy, which was found by our 3 studies and 1 other study. There were mixed findings for whole brain parenchyma, cortical gray matter, and SCN+IFT, with some studies showing atrophy and others showing enlargement. The reasons for the different findings were unclear but may have been due to multiple differences in methods, including brain volumetry software, patient samples (including nature and severity of injury), and time after injury. However, the NeuroQuant® database used in the current study may have constituted a better normal control group than those of other studies because it was based on a much higher number of controls (over 4,000 throughout the lifespan) and because it was the only one FDA-cleared for clinical use. Overall, it seemed likely that longitudinal atrophy of cerebral white matter, enlargement of cortical gray matter, and enlargement of SCN+IFT was a characteristic of at least some patients with chronic mild or moderate TBI.

**Implications of longitudinal versus cross-sectional design.** Since the current findings partially replicated and extended
| Study | Patients with longitudinal data | Control participants | Methods | Significant longitudinal findings |
|-------|---------------------------------|----------------------|---------|----------------------------------|
| Hofman\(^6\) | 21 patients with mTBI: 12 with MRI lesions visible on t1, and 9 with normal-appearing MRI | None | t1: around 4 days after injury. t1-t2 interval: around 6 months in duration. Semi-auto- mated volumetry. \(\text{tVBR} = \frac{\text{t1_VBR}}{\text{t2_VBR}}\) | Patients with abnormal-appearing MRIs had whole brain atrophy longitudi- nally (based on decrease of tVBR). |
| MacKenzie\(^7\) | 7 patients with mild or moderate TBI | 4 normal controls | t1: around 14 months after injury. t1-t2 interval: around 1 year in duration. Semi-auto- mated volumetry. | WBP atrophy and CSF enlargement. |
| Ross\(^8\) | 16 patients with mTBI | 20 normal controls | t1 was around 2 years after injury; t1-t2 interval: around 1 year in duration. | Atrophy of WBP, forebrain parenchyma, CWM, and cerebellum. |
| Ling\(^20\) | 26 patients with mTBI | 26 normal controls | t1: around 14 days after injury. t2: around 4 months after injury. FreeSurfer was used to measure cortical thickness and volume. | None. |
| Zhou\(^9\) | 19 patients with mTBI | 12 controls | t1: around 23 days after injury. t1-t2 interval: around 13 months in duration. FreeSurfer was used to measure volume. | Atrophy of anterior cingulate WM, cingulate gyrus isthmus WM, precuneal GM, inferior and medial orbital frontal regions, olfactory frontal regions. |
| Ross\(^12\) | 26 patients with mild or moderate TBI | 20 normal controls | t1: mean 1.7 years after injury. t2: mean 3.4 years after injury. Brain volume was estimated at time 0 \((t0)\) just before injury. NeuroQuant\(^8\) and NeuroGage\(^8\) were used to estimate (at t0) and measure (at t1 and t2) brain volume. | From t0-t1, WBP and CWM atrophied, and SCN+IFT enlarged. Enlargement of SCN+IFT from t0-t1 correlated with cross-sectional enlargement (at t1) of cerebellum and brainstem. For t1-t2, WBP and CWM atrophied. |
| Wang\(^13\) | 11 patients with mTBI | 12 patients without TBI | t1: around 7 days after injury. t2: around 4 months after injury. FreeSurfer used to measure cortical thickness. | Rostral middle frontal gyrus cortical thickness decreased in the mTBI group but not in the non-TBI group |
| Govinda-rajan\(^15\) | 33 patients with mTBI treated with atorva- statin. 38 patients with mTBI not-treated. | 60 orthopedic controls. | t1: around 24 hours after injury. t2: around 3 months after injury. FreeSurfer was used to measure cortical thickness and brain volume. | Combined patient group had cortical thinning of multiple cortical regions in the frontal, temporal and parietal lobes. Combined patient group had cortical thickening of insula, anteri- or cingulate and superior parietal regions. Non- |

(continued)
our previous findings, why are they important? Our previous studies were based mostly on cross-sectional data. The current study was based mainly on longitudinal (t1-t2) data, thus providing a new basis for important theoretical implications, as discussed below in this section. Because atrophy after TBI has been reported commonly, we will focus our discussion on the newer findings of widespread enlargement.

As a first step toward understanding why the enlargement occurs, it is important to consider when it occurs and to ask what might cause abnormal brain enlargement during different time periods after injury.

**Before injury:** Our patients were carefully selected to exclude those with brain disorders that would have affected pre-injury brain volume. The longitudinal results, enlargement during the chronic stage, showed that enlargement did not occur only during the pre-injury stage. Based on these two reasons, it is parsimonious to conclude that enlargement did not occur before injury.

**Acute stage (0-1 week after injury):** It is well-known that in patients with severe TBI, the brain swells acutely after injury. So it would not be surprising for the same phenomenon to occur to a lesser degree in patients with mild TBI. On the other hand, acute edema after injury in severe TBI usually resolves within days to a couple weeks, making it less clear if acute neuroinflammation would cause chronic enlargement in patients with mild or moderate TBI. Our longitudinal results showed that enlargement did not occur only during the acute stage, but remains possible that enlargement occurred also during this stage.

**Subacute stage (1 week to 3 months after injury):** Our results suggested that there was cross-sectional enlargement during this stage, based on moderate to large effect sizes observed in a subsample of patients scanned during this stage (see Figures 1 to 4 from19 and Figures 3 to 5 in the current submission). Since it is unlikely that patients had enlargement before injury, it seems likely that the observed cross-sectional enlargement was due to longitudinal enlargement, but this hypothesis should be directly tested when data become available. The leading candidates for mechanisms include compensatory hypertrophy and neuroinflammation (see the Theoretical importance of abnormal enlargement section). Since neuroinflammation begins in the acute stage, and since compensatory hypertrophy would take days to weeks to develop, the different possible causes of enlargement may have different time courses.

**Chronic stage:** Our results showed that there was cross-sectional and longitudinal enlargement during this stage. The leading candidates for mechanisms include compensatory hypertrophy and chronic neuroinflammation (see the Theoretical importance of abnormal enlargement section).

**Abnormal cross sectional brain volume**

At t2, the patients (N = 36) had many regions that were abnormally large and a few that were abnormally small. The pattern of abnormal volumes was very similar to that observed in our previous study which examined t1 volumes using a group of patients that was mostly overlapping but larger (N = 50) than in the current study because more data were available at t1 than t2.19 Thus, although the current study’s t1-t2 analyses showed multiple significant increases of volume, the changes were not large enough to have a major impact on the pattern of cross-sectional volume abnormalities at t1 compared to t2.

**Theoretical importance of abnormal enlargement**

What causes the abnormal brain volume enlargement in patients with chronic mild or moderate TBI? Two leading possibilities include compensatory hypertrophy and chronic neuroinflammation.

**Compensatory hypertrophy.** Regarding possible compensatory hypertrophy, there have been many studies...
showing that when brain regions perform more tasks, they enlarge.47–60

There are a few possible causes or subcategories of the hypothesized compensatory hypertrophy that are discussed below, including: 1) injured brain regions become more active and enlarge; 2) uninjured brain regions connected to the injured brain regions become more active and enlarge; and 3) the injured regions atrophied in the post-injury acute phase and later enlarged as recovery occurred.

Subhypothesis 1: the injured brain regions become more active and enlarge. This is supported by studies of patients with brain disorders showing that increased brain activity leads to brain enlargement.47,55,59,60

Subhypothesis 2: uninjured brain regions account for the enlargement. This is indirectly supported by studies of people without brain disorders showing that increased brain activity leads to brain enlargement.48–54,56–58

Subhypothesis 3: reversal of previous atrophy. Under this scenario, the observed longitudinal enlargement would be consistent with brain regions changing from abnormally small to normal cross-sectional volume. However, this hypothesis would not explain the abnormal cross-sectional enlargement reported in this and other studies12,13,15,19 and therefore seems unlikely to be true.

Chronic neuroinflammation. An alternative explanation for the cause of the brain enlargement is chronic neuroinflammation. Previous investigators have found that TBI causes both acute and chronic neuroinflammation,61–68 which can persist for years after injury.63 So it would be reasonable to hypothesize that chronic neuroinflammation and edema result in abnormally large brain volume.

Empirical evidence for this idea comes from a study of a group of patients with mild TBI, which found that abnormal enlargement of the anterior and posterior cingulate regions was associated with posttraumatic headache and a serum marker of neuroinflammation.69 In a post hoc attempt to explore this possibility, we attempted to partially replicate their findings.

Each of our patients was assessed for posttraumatic headaches using the approach recommended by Zasler et al.,70 pp. 932–953, including the most common types of posttraumatic headaches—tension-type, neuropathic (also called neuralgia) and migraines,70 p. 949. T-tests were performed within between subgroups of patients based on headache type to test the hypotheses that each headache type was associated with volume abnormalities in the anterior or posterior cingulate gyrus.

Results showed that patients with neuropathic headaches had larger volume of the posterior cingulate cortex (P = .01), with a medium-to-large effect size, although the P value did not survive Bonferroni adjustment (adjusted alpha = .05/6 tests = .008) (Table 5). Given the a priori finding of an association, the Bonferroni adjustment may have been too conservative.46 Overall, this finding of an association between the neuropathic headaches and abnormal enlargement of the posterior cingulate cortex provided moderately good support for the previous similar finding by Niu et al.69

As those authors pointed out, there is a higher prevalence of chronic posttraumatic headache in mild TBI than in moderate or severe TBI, which is surprising because most symptoms are less severe in mild TBI. Similarly, abnormal enlargement appears to occur more often in mild TBI, which is surprising because most volume abnormalities have been reported to occur less often in mild TBI. Given these similarities

| Headache type | Anterior cingulate volume | Posterior cingulate volume |
|---------------|---------------------------|---------------------------|
|               | Mean | SD  | t   | df | P    | Effect size | Mean | SD  | t   | df | P    | Effect size |
| Tension-type  |      |     |     |    |      |             |      |     |     |    |      |             |
| Yes           | 15   | 0.20| 22.2| 0.06| 0.64 |              | 0.37 | 1.10|     |    |      |              |
| No            | 39   | 0.70| 1.29|     |      |              | 0.79 | 0.99|     |    |      |              |
| Neuropathic   |      |     |     |    |      |             |      |     |     |    |      |             |
| Yes           | 28   | 0.72| 1.45|     |      |              | 1.00 | 0.82|     |    |      |              |
| No            | 26   | 0.15| 1.32|     |      |              | 0.32 | 1.12|     |    |      |              |
| Migraine      |      |     |     |    |      |             |      |     |     |    |      |             |
| Yes           | 28   | 0.55| 1.35|     |      |              | 0.50 | 1.07|     |    |      |              |
| No            | 26   | 0.34| 1.48|     |      |              | 0.86 | 0.97|     |    |      |              |

The results showed that neuropathic headaches were associated with enlargement of the posterior cingulate gyrus.

* Asterisks and bold font indicate regions associated with P values < .05. No regions were associated with Bonferroni-adjusted P values < .008 (= 0.05/6 tests). See the Discussion section for further discussion.
and our replication of Niu and colleagues’ finding of an association between posttraumatic headaches and cingulate enlargement, it is interesting to hypothesize that these phenomena share a pathophysiology that occurs more often in mild TBI than in severe TBI.

Niu et al. provided a theoretical framework for our hypothesis based in part on their finding that posttraumatic headaches were associated with increased serum levels of CCL2, a chemokine that increases rapidly after TBI, causing inflammation. Accordingly, Niu et al. hypothesized that TBI leads to inflammation, causing gray matter hyperreactivity, volume increase and altered pain perception.

**Limitations**

The current study examined patients with mild or moderate TBI who had symptoms that persisted for months to years after the injury and sought treatment at a TBI specialty clinic. Therefore, these results may not apply to other TBI patients, for example, patients with severe TBI, or patients with mild TBI who have complete resolution of symptoms within hours to days. Also, given the naturalistic outpatient setting of the current study, the patients participated in rehabilitation, and most of them took neuropsychiatric medications for their symptoms. It was unknown whether those factors affected brain volume.

Limitations of the current study included that it was not possible to definitively evaluate the effects of education on the findings because education data was not available for the NeuroQuant® normal controls. However, given that the mean years of education for the patients (14.3; SD = 3.0) was similar to the mean years of education for the U.S.A. population in 2012 (13.3 years), it seemed unlikely that there would have been large effects of education on brain volume. It would be helpful for future studies to include measurements of levels of education.

Many of the patients in the current study had posttraumatic stress disorder (PTSD). A recent review found that PTSD is associated with atrophy of gray and white matter in prefrontal cortex and cingulate cortex; atrophy of the corpus callosum and hippocampus; and abnormal enlargement of the amygdala.71 The findings of atrophy of the cerebral white matter overlaps with the same finding in the current study and many other studies of TBI. The finding of abnormal enlargement of the amygdala also overlaps with the same finding in the current study. However, the finding of atrophy of cortical gray matter regions and the hippocampus, although overlapping with studies of moderate and severe TBI, stand in contrast to the current findings of abnormal enlargement of those structures. Thus, there were some findings from the current study which may have been due to TBI or PTSD, but other findings appeared to be relatively specific to chronic mild or moderate TBI. Further research on patients with and without TBI, and with and without PTSD, will be needed to further clarify these issues.

To measure brain volume, this study used NeuroQuant software instead of better-known programs like FreeSurfer or other programs commonly used in university research settings. A PubMed search showed that there have been many more peer-reviewed published articles using FreeSurfer (1946 articles) than NeuroQuant® (91 articles). Why use software that has many less publications to support it?

Although NeuroQuant has fewer peer-reviewed articles to support its use, 91 articles and FDA clearance provide a good basis for its reliability and validity, as discussed in the NeuroQuant® software was used for cross-sectional brain volume analysis section.

Furthermore, most or all clinical researchers agree that university-based research findings should provide benefits or applications for patients in real-world clinical settings. However, there is a large gap between the research on advanced MRI brain imaging techniques and their clinical availability.72,73 In clinical practice, to order a brain volume analysis of a patient, the clinician must choose a software tool that has not only a sound research basis but also commercial availability. In 2007, NeuroQuant® achieved both goals, and now it is relatively easy for a clinician to order a brain volume analysis on a patient.

In contrast, FreeSurfer and similar programs are not available for use in typical clinical settings. This is due in part to the fact that FreeSurfer and most university research-based programs are not FDA-cleared and do not have large, well-characterized and well-controlled normal control datasets that allow reliable and valid analyses on individual subjects.

NeuroQuant® generally has been found to have good to excellent reliability with FreeSurfer by our group,33,34 and others.30,35,40,74 Given the multiple studies showing good inter-method reliability and other types of reliability for NeuroQuant®,8,75,76 we believe that it is likely that the results of the current study would show good reliability with results from studies using programs like FreeSurfer. Nevertheless, it will be important to test this idea directly.

Finally, we will discuss the limitations of the brain volume estimation method, a relatively novel method. The t0-t1 longitudinal analyses were based on estimation, not measurement, of brain volume at t0 (time of injury). Actual measurement of volume at t0 before accidental injury would have been highly preferable. However, this approach would be difficult and expensive because many healthy people would need to be
scanned for every one who subsequently had a TBI. For this reason, a study of this type has never been done, and the volume estimation method was developed as a partial solution to this problem.

How reliable is the volume estimation method? The reliability of estimated versus measured volumes was good for the 4 large brain regions used in the current study. Not surprisingly, test-retest reliabilities for estimated-versus-measured volumes were lower than for measured-versus-measured volumes, which had excellent reliability.

Furthermore, due to the lower reliabilities for estimated-versus-measured volumes, the variances for t0-t1 change data were markedly larger than for t1-t2 change data. An example of this can be seen in Figures 1 and 2, where the normal range for t0-t1 cortical gray matter volume change at 45 years of age was -0.1% ± 7.6% per year (Figure 1), whereas the corresponding range for t1-t2 change was -0.2% ± 2.3% per year (Figure 2). But despite the greater variances for t0-t1 data, the current study still found statistically significant t0-t1 volume changes for all 4 brain regions.

Is estimation of volume change from t0-t1 more informative than cross-sectional measurement at t1? Cross-sectional volumes at t1 adjust for intracranial volume, so in some sense they are similar to t0 volume estimation, which uses measurement of intracranial volume as a core feature. But cross-sectional volumes do not take advantage of the longitudinal design, which often is more sensitive for detecting brain volume abnormalities. For example, previously we reported that a subset (N = 50) of the current sample of patients (N = 55) did not have statistically significant cross-sectional atrophy of cerebral white matter (effect size = -2.3; \( P = .13 \)) (although other evidence showed that there likely was atrophy, especially within the first 10 months of injury). In contrast, in the current study, the longitudinal t0-t1 analyses found statistically significant cerebral white matter atrophy (effect size = -3.1; \( P = .005 \)); the effect size was 35% larger (\( = [0.8/2.3] \times 100\% \)), due mainly to the increased power of the longitudinal design. Thus, the t0-t1 analysis, in comparison with the t1 cross-sectional analysis, provided clearer statistical evidence for the finding of cerebral white matter atrophy.

Similarly, the t0-t1 estimates of volume change complement the t1-t2 measured data because, unlike the t1-t2 data, they cover the acute and subacute stages after injury.

In summary, compared to actually measuring volume at t0, estimating volume at t0 is an inferior method. But compared to not having a measurement or even estimate of volume change during the critically important t0-t1 interval, estimating t0-t1 volume change is a useful approach based on its reliability and validity for distinguishing patients from normal controls. Therefore, the best approach may be to combine t0-t1 estimates with traditional cross-sectional and longitudinal measurements.

**Conclusions**

In contrast to previous studies that found longitudinal brain volume decrease in patients with chronic mild or moderate TBI, the current study found more longitudinal brain volume enlargement than atrophy. However, there was atrophy in some regions. An almost universal limitation in this area is the lack of brain volume measurement before injury. Given this limitation, one of the most interesting aspects of the current finding of post-injury longitudinal increase of volume is that it adds indirect evidence that the previous findings of cross-sectional enlargement were due to post-injury enlargement and not due to pre-injury abnormalities. This conclusion is based on the idea that, because the current study found that longitudinal enlargement occurred after injury (with t1 and t2 both measured after injury), then it was more likely that longitudinal enlargement also occurred earlier in the post-injury course (between t0 and t1).

The finding that chronic mild or moderate TBI is characterized by cross-sectional and longitudinal brain volume enlargement stands in contrast to many previous studies of patients with moderate to severe TBI, which have consistently found brain atrophy. In turn, the contrasting findings suggest that mild TBI is not simply a mild form of severe TBI but is fundamentally different with respect to brain volume changes and pathophysiology, raising hope—for example—that treatments that did not work for severe TBI might work for mild to moderate TBI. Other ideas for future research include measuring volume change closer to the time of injury, and examination of correlations between volume changes and changes in pathophysiological measures (including measures of neuroinflammation), neuropsychological performance or clinical symptoms.

**Acknowledgements**

The following information is required to be included in publications that used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. Data used in the preparation of this article were obtained from the ADNI database (adni.loni.ucla.edu). The ADNI was launched in 2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-private partnership. The primary goal of ADNI has been to test whether serial magnetic resonance imaging...
(MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). The Principal Investigator of this initiative is Michael W. Weiner, M.D., VA Medical Center and University of California - San Francisco. ADNI is the result of efforts of many co-investigators from a broad range of academic institutions and private corporations, and subjects have been recruited from over 50 sites across the U.S. and Canada. MRI data collection and sharing for the ADNI normal control participants was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.;Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Declaration of conflicting interests
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ross is CEO of NeuroGage LLC, a company which produces Neurogage® software. In 2017, he was a paid consultant for CorTechs Labs, Inc., which produces NeuroQuant® software. None of the other authors had competing interests.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
David E Ross https://orcid.org/0000-0001-9189-2806
Jason A Burton https://orcid.org/0000-0003-0765-9740

References
1. Bigler ED. Structural imaging. In: Silver JM, McAllister TW and Yudofsky SC (eds) Textbook of traumatic brain injury. Washington, DC: American Psychiatric Publishing, Inc., 2005, pp.79–105.
2. Bigler ED. Structural imaging. In: Silver JM, McAllister TW and Yudofsky SC (eds) Textbook of traumatic brain injury. 2nd ed. Washington, DC: American Psychiatric Publishing, Inc., 2011, pp.73–90.
3. Wilde EA and Little D. Clinical imaging. In: Silver JM, McAllister TW and Arciniegas DB (eds) Textbook of traumatic brain injury. Washington, DC: American Psychiatric Association Publishing, 2019, pp.89–126.
4. Ross DE, Ochs AL, Seabaugh JM, et al. Man vs. machine: comparison of radiologists’ interpretations and NeuroQuant® volumetric analyses of brain MRIs in patients with traumatic brain injury. J Neuropsychiatry Clin Neurosci 2013; 25: 1–8.
5. Ross DE, Ochs AL, DeSmit ME, et al. Man vs. machine part 2: comparison of radiologists’ interpretations and NeuroQuant® measures of brain asymmetry and progressive atrophy in patients with traumatic brain injury. J Neuropsychiatry Clin Neurosci 2015; 27: 147–152.
6. Hofman PA, Stapert SZ, van Kroonenburgh MJ, et al. MR imaging, single-photon emission CT, and neurocognitive performance after mild traumatic brain injury. AJNR Am J Neuroradiol 2001; 22: 441–449.
7. MacKenzie JD, Siddiqi F, Babb JS, et al. Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. Am J Neuroradiol 2002; 23: 1509–1515.
8. Ross DE, Ochs AL, Seabaugh JM, et al. Progressive brain atrophy in patients with chronic neuropsychiatric symptoms after mild traumatic brain injury: a preliminary study. Brain Inj 2012; 26: 1500–1509.
9. Zhou Y, Kierans A, Kenul D, et al. Mild traumatic brain injury: longitudinal regional brain volume changes. Radiology 2013; 267: 880–890.
10. Toth A, Kovacs N, Perlaki G, et al. Multi-modal magnetic resonance imaging in the acute and sub-acute phase of mild traumatic brain injury: can we see the difference? J Neurotrauma 2013; 30: 2–10.
11. Maller JJ, Thomson RH, Pannek K, et al. Volumetrics relate to the development of depression after traumatic brain injury. Behav Brain Res 2014; 271: 147–153.
12. Ross DE, Ochs AL, Zannoni MD, et al. Back to the future: estimating pre-injury brain volume in patients with traumatic brain injury. NeuroImage 2014; 102: 565–578.
13. Wang X, Xie H, Cotton A, et al. Early cortical thickness change after mild traumatic brain injury following motor vehicle collision. J Neurotrauma 2015; 32: 455–463.
14. Epstein DJ, Legarreta M, Buler E, et al. Orbitofrontal cortical thinning and aggression in mild traumatic brain injury patients. Brain Behav 2016; 6: 1–10.
15. Govindarajan KA, Narayana PA, Hasan KM, et al. Cortical thickness in mild traumatic brain injury. J Neurotrauma 2016; 33: 1809–1817.
16. Ross DE, Ochs AL, Zannoni MD, et al. Corrigendum to “back to the future: Estimating Pre-Injury brain volume
in patients with traumatic brain injury” [NeuroImage 102 (Part 2) (15 November 2014) 565–578]. NeuroImage 2016; 127: 510–511.

17. Zagorchev L, Meyer C, Stehle T, et al. Differences in regional brain volumes two months and one year after mild traumatic brain injury. J Neurotrauma 2016; 33: 29–34.

18. Rajesh A, Cooke GE, Monti JM, et al. Differences in brain architecture in remote mild traumatic brain injury. J Neurotrauma 2017; 34: 3280–3287.

19. Ross DE, Seabaugh JD, Seabaugh JM, et al. Patients with chronic mild or moderate traumatic brain injury have abnormal brain enlargement. Brain Inj 2020; 34: 11–19.

20. Ling JM, Klimaj S, Toulouse T, et al. A prospective study of gray matter abnormalities in mild traumatic brain injury. Neurology 2013; 81: 2121–2127.

21. Ross DE. Review of longitudinal studies of MRI brain volumetry in patients with traumatic brain injury. Brain Inj 2011; 25: 1271–1278.

22. Menon DK, Schwab K, Wright DW, et al. Position statement: definition of traumatic brain injury. Arch Phys Med Rehabil 2010; 91: 1637–1640.

23. Silver JM, McAllister TW and Yudofsky SC. Textbook of traumatic brain injury. 2nd ed. Arlington, VA: American Psychiatric Publishing, Inc., 2011.

24. Wilson JT, Pettigrew LE and Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma 1998; 15: 573–585.

25. Ross DE, Seabaugh J, Cooper L, et al. NeuroQuant® and NeuroGage® reveal effects of traumatic brain injury on brain volume. Brain Inj 2018; 32: 1437–1441.

26. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 2010; 74: 201–209.

27. Weiner MW, Aisen PS, Jack CR Jr, et al. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6: 202–211.

28. Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav Neurol 2009; 21: 21–28.

29. Kovacevic S, Rafii MS and Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Dis Assoc Disord 2009; 23: 139–145.

30. Huppertz H-J, Kröll-Seiger J, Klöppel S, et al. Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. NeuroImage 2010; 49: 2216–2224.

31. Ross DE, Graham TJ and Ochs AL. Review of the evidence supporting the medical and forensic use of NeuroQuant® in patients with traumatic brain injury. Psychol Inj Law 2012; 5: 1–6.

32. Ochs AL, Ross DE, Zannoni MD, et al. Comparison of automated brain volume measures obtained with NeuroQuant and FreeSurfer. J Neuroimaging 2015; 25: 721–727.

33. Ross DE, Ochs AL, Tate DF, et al. High correlations between MRI brain volume measurements based on NeuroQuant® and FreeSurfer. Psychiatry Res Neuroimaging 2018; 278: 69–76.

34. Reid MW, Hannemann NP, York GE, et al. Comparing two processing pipelines to measure subcortical and cortical volumes in patients with and without mild traumatic brain injury. J Neuroimaging 2017; 27: 365–371.

35. Moen KG, Skandsen T, Folvik M, et al. A longitudinal MRI study of traumatic axonal injury in patients with moderate and severe traumatic brain injury. J Neurol Neurosurg Psychiatry 2012; 83: 1193–1200.

36. Ross DE, Ochs AL, Seabaugh J, et al. NeuroQuant® revealed hippocampal atrophy in a patient with traumatic brain injury. J Neuropsychiatry Clin Neurosci 2012; 24: E33–E33.

37. Ross DE, Castelvecchi C and Ochs AL. Brain MRI volumetry in a single patient with mild traumatic brain injury. Brain Inj 2013; 27: 634–636.

38. Brezova V, Moen KG, Skandsen T, et al. Prospective longitudinal MRI study of brain volumes and diffusion changes during the first year after moderate to severe traumatic brain injury. NeuroImage Clin 2014; 5: 128–140.

39. Wright KL, Hopkins RO, Robertson FE, et al. Assessment of white matter integrity after pediatric traumatic brain injury. J Neurotrauma 2020; 37: 2188–2197. DOI:10.1089/neu.2019.6691.

40. Vanier C, Pandey T, Parikh S, et al. Interval-censored survival analysis of mild traumatic brain injury with outcome-based neuroimaging clinical applications. J Concussion 2020; 4: 1–13.

41. Ross DE, Graham TJ and Ochs AL. Review of the evidence supporting the medical and forensic use of NeuroQuant® in patients with traumatic brain injury. Psychol Inj Law 2013; 6: 75–80.

42. Hedman AM, van Haren NEM, Schnack HG, et al. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Mapp 2012; 33: 1987–2002.

43. Shrout PE and Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979; 86: 420–428.

44. Koo TK and Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 2016; 15: 155–163.

45. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43–46.

46. Han K, Davis RA, Chapman SB, et al. Strategy-based reasoning training modulates cortical thickness and resting-state functional connectivity in adults with chronic traumatic brain injury. Brain Behav 2017; 7: e00687.

47. Mogilner A, Grossman J, Ribary U, et al. Somatosensory cortical plasticity in adult humans revealed by magnetoencephalography. Proc Natl Acad Sci U S A 1993; 90: 3593–3597.
49. Ramachandran VS and Hirstein W. The perception of phantom limbs. The D. O. Hebb lecture. *Brain* 1998; 121: 1603–1630.

50. Merzenich M, Nelson RJ, Stryker MP, et al. Somatosensory cortical map changes following digit amputation in adult monkeys. *J Comp Neurol* 1984; 224: 591–605.

51. Chen R, Cohen L and Hallett M. Nervous system reorganization following injury. *Neuroscience* 2002; 111: 761–773.

52. Maguire EA, Gadian DG, Johnsrude IS, et al. Navigation-related structural change in the hippocampi of taxi drivers. *Proc Natl Acad Sci USA* 2000; 97: 4398–4403.

53. Gaser C and Schlaug G. Brain structures differ between musicians and non-musicians. *J Neurosci* 2003; 23: 9240–9245.

54. Driemeyer J, Boyke J, Gaser C, et al. Changes in gray matter induced by learning-revisited. *PLoS One* 2008; 3: e2669.

55. Lazaridou A, Astrakas L, Mintzopoulos D, et al. Diffusion tensor and volumetric magnetic resonance imaging using an MR-compatible hand-induced robotic device suggests training-induced neuroplasticity in patients with chronic stroke. *Int J Mol Med* 2013; 32: 998–1000.

56. Erickson K, Voss M, Prakash R, et al. Exercise training increases size of hippocampus and improves memory. *Proc Natl Acad Sci U S A* 2011; 108: 3017–3022.

57. Metzler-Baddeley C, Caeyenberghs K, Foley S, et al. Task complexity and location specific changes of cortical thickness in executive and salience networks after working memory training. *Neuroimage* 2016; 130: 48–62.

58. Wenger E, Kuhn S, Verrel J, et al. Repeated structural imaging reveals nonlinear progression of experience-dependent volume changes in human motor cortex. *Cereb Cortex* 2017; 27: 2911–2925.

59. Caeyenberghs K, Clemente A, Imms P, et al. Evidence for training-dependent structural neuroplasticity in brain-injured patients: a critical view. *Neurorehabil* 2018; 32: 99–114.

60. Keller J, Štětkářová I, Macri V, et al. Virtual reality-based treatment for regaining upper extremity function induces cortex grey matter changes in persons with acquired brain injury. *J Neuroeng Rehabil* 2020; 17: 127.

61. Donkin JJ and Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. *Curr Opin Neurol* 2010; 23: 293–299.

62. Bigler ED and Maxwell WL. Neuropathology of mild traumatic brain injury: relationship to neuroimaging findings. *Brain Imaging Behav* 2012; 6: 108–136.

63. Johnson VE, Stewart JE, Begbie FD, et al. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. *Brain* 2013; 136: 28–42.

64. Finnie JW. Neuroinflammation: beneficial and detrimental effects after traumatic brain injury. *Inflammopharmacol Inflammopharmacol* 2013; 21: 309–320.

65. Smith C, Gentleman SM, Leclercq PD, et al. The neuro-inflammatory response in humans after traumatic brain injury. *Neuropathol Appl Neurobiol* 2013; 39: 654–666.

66. Kou Z and VandeVord PJ. Traumatic white matter injury and glial activation: from basic science to clinics. *Glia* 2014; 62: 1831–1855.

67. Lozano D, Gonzales-Portillo GS, Acosta S, et al. Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. *Dis Treat* 2015; 2015: 97–106.

68. Taib T, Leconte C, Van Steenwinckel J, et al. Neuroinflammation, myelin and behavior: temporal patterns following mild traumatic brain injury in mice. *PLoS One* 2017; 12: e0184811.

69. Niu X, Bai L, Yingxiang S, et al. Mild traumatic brain injury is associated with effect of inflammation on structural changes of default mode network in those developing chronic pain. *J Headache Pain* 2020; 21: 135.

70. Zasler ND, Katz DI and Zafonte RD. *Brain injury medicine: Principles and practice*. 2nd ed. New York, NY: Demos Medical Publishing, 2013.

71. Moyer A. Post-traumatic stress disorder and magnetic resonance imaging. *Radiol Technol* 2016; 87: 649–667.

72. Wintemberg M, Coombs L, Druzgal TJ, et al. Traumatic Brain Injury Imaging Research Roadmap. 2014; 36: E12–E23.

73. Wintemberg M, Sanelli PC, Anzai Y, et al. Imaging evidence and recommendations for traumatic brain injury: advanced neuro- and neurovascular imaging techniques. *AJNR Am J Neuroradiol* 2015; 36: E1–E11.

74. Chung J, Kim H, Moon Y, et al. Comparison of vendor-provided volumetry software and NeuroQuant using 3D T1-weighted images in subjects with cognitive impairment: how large is the inter-method discrepancy? *Investig Magn Reson Imaging* 2020; 24: 76–84.

75. Wang C, Beadnell HN, Hatton SN, et al. Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. *J Neurol Neurosurg Psychiatry* 2016; 87: 754–757.

76. Brewer JB, Magda S, Airriess C, et al. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. *AJNR Am J Neuroradiol* 2009; 30: 578–580.